Business Context and Reporting Period
This Form 8-K is a current report filed by OncoGenex Pharmaceuticals, Inc. (noting a discrepancy with the metadata company name "ACHIEVE LIFE SCIENCES, INC.") on February 19, 2010. The report addresses the departure of the Company's Chief Financial Officer, Steve Anderson, effective February 24, 2010.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive compensation and personnel changes rather than financial performance metrics.
Material Changes
The primary material change is the termination of the employment of Steve Anderson, the Chief Financial Officer. In connection with his departure, the Company entered into an amendment to his employment agreement on February 24, 2010, which includes:
- Extension of the severance payment period from nine months to nine months and 12 days.
- Provision of one month's base compensation in lieu of notice.
- Immediate lapse of time-based vesting restrictions on equity awards that would have vested through December 31, 2010, rather than the original December 19, 2010 date.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, or management commentary regarding future financial performance. The primary risk disclosed is the loss of a senior executive (CFO) and the associated immediate financial impact of the amended severance and equity vesting terms.
Investor Verification Checklist
- Verify the correct registrant name (OncoGenex Pharmaceuticals, Inc. vs. metadata "ACHIEVE LIFE SCIENCES, INC.").
- Confirm the total cost of the amended severance package and accelerated equity vesting.
- Identify the interim or permanent replacement for the Chief Financial Officer.
- Review the attached press release (Exhibit 99.1) for additional context on the departure.